Frazier Life Sciences Public Fund, L.P. has announced an increase in its ownership stake in Phathom Pharmaceuticals, Inc. to 6.5%. This significant investment underscores Frazier's ongoing confidence in the pharmaceutical sector, particularly as Phathom continues to develop its pipeline of therapies.

According to the recent SEC filing, dated November 2, 2026, Frazier Life Sciences has acquired a total of 5,323,356 shares of Phathom's common stock. This move positions Frazier as a notable shareholder in Phathom, reflecting its strategy to influence corporate governance and strategic direction.

Background

Frazier Life Sciences Public Fund, L.P. is a Delaware-based investment firm focusing on the life sciences sector. The firm is known for its strategic investments in companies that are developing innovative therapies and treatments. The recent filing is part of a series of disclosures that highlight Frazier's active role in the pharmaceutical industry.

Phathom Pharmaceuticals, Inc., the subject of this investment, operates under the SIC classification of Pharmaceutical Preparations [2834]. The company is engaged in developing treatments for gastrointestinal diseases, showcasing its commitment to addressing unmet medical needs.

What the Filing Says

The filing indicates that Frazier Life Sciences Public Fund holds 5,323,356 shares of Phathom Pharmaceuticals, representing 6.5% of the company’s outstanding shares. The filing states, "The percentage listed in row 13 is calculated based on 81,291,520 shares of the Issuer's Common Stock outstanding as of October 27, 2026." This substantial stake reflects Frazier's confidence in Phathom's future prospects.

Impact

This increase in ownership may influence Phathom's strategic decisions and corporate governance, as Frazier Life Sciences is known for its active involvement in the companies it invests in. Other significant shareholders include FHMLSP, L.P. and Frazier Life Sciences IX, L.P., which also hold considerable stakes in Phathom, indicating a collective interest in the company's direction.

What's Next

The filing does not specify what actions Frazier Life Sciences plans to take next regarding its investment in Phathom Pharmaceuticals. However, given the nature of such filings, it is likely that further disclosures will follow as the relationship between the two entities evolves.

This recent development highlights the competitive landscape within the pharmaceutical industry, where strategic investments can significantly impact a company's trajectory and stakeholder dynamics.